Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Geron Corporation
Uwe Platzbecker; Valeria Santini; Pierre Fenaux; Mikkael A Sekeres; Michael R Savona; Yazan F Madanat; Maria Díez-Campelo; David Valcárcel; Thomas Illmer; Anna Jonášová; Petra Bělohlávková; Laurie J Sherman; Tymara Berry; Souria Dougherty; Sheetal Shah; Qi Xia; Libo Sun; Ying Wan; Fei Huang; Annat Ikin; Shyamala Navada; Faye Feller; Rami S Komrokji; Amer M Zeidan